Translating the science of aging into therapeutic interventions

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Life and health span have been extended in experimental animals using drugs that are potentially translatable into humans. Considerable effort is needed beyond the usual steps in drug development to devise the models, and realistic preclinical and clinical trial strategies are required to advance these agents into clinical application. It will be important to focus on subjects who already have symptoms or are at imminent risk of developing disorders related to fundamental aging processes, to use short-term, clinically relevant outcomes, as opposed to long-term outcomes, such as health span or life span, and to validate endpoint measures so they are acceptable to regulatory agencies. Funding is a roadblock, as is shortage of investigators with combined expertise in the basic biology of aging, clinical geriatrics, and investigational new drug clinical trials. Strategies for developing a path from the bench to the bedside are reviewed for interventions that target fundamental aging mechanisms.

Original languageEnglish (US)
Article numbera025908
JournalCold Spring Harbor perspectives in medicine
Volume6
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Aging of materials
Clinical Trials
Investigational Drugs
Health
Geriatrics
Pharmaceutical Preparations
Research Personnel
Animals
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Translating the science of aging into therapeutic interventions. / Kirkland, James L.

In: Cold Spring Harbor perspectives in medicine, Vol. 6, No. 3, a025908, 01.03.2016.

Research output: Contribution to journalArticle

@article{9c6480e2fc99431e8ee628eeb2463d72,
title = "Translating the science of aging into therapeutic interventions",
abstract = "Life and health span have been extended in experimental animals using drugs that are potentially translatable into humans. Considerable effort is needed beyond the usual steps in drug development to devise the models, and realistic preclinical and clinical trial strategies are required to advance these agents into clinical application. It will be important to focus on subjects who already have symptoms or are at imminent risk of developing disorders related to fundamental aging processes, to use short-term, clinically relevant outcomes, as opposed to long-term outcomes, such as health span or life span, and to validate endpoint measures so they are acceptable to regulatory agencies. Funding is a roadblock, as is shortage of investigators with combined expertise in the basic biology of aging, clinical geriatrics, and investigational new drug clinical trials. Strategies for developing a path from the bench to the bedside are reviewed for interventions that target fundamental aging mechanisms.",
author = "Kirkland, {James L}",
year = "2016",
month = "3",
day = "1",
doi = "10.1101/cshperspect.a025908",
language = "English (US)",
volume = "6",
journal = "Cold Spring Harbor perspectives in medicine",
issn = "2157-1422",
publisher = "Cold Spring Harbor Laboratory Press",
number = "3",

}

TY - JOUR

T1 - Translating the science of aging into therapeutic interventions

AU - Kirkland, James L

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Life and health span have been extended in experimental animals using drugs that are potentially translatable into humans. Considerable effort is needed beyond the usual steps in drug development to devise the models, and realistic preclinical and clinical trial strategies are required to advance these agents into clinical application. It will be important to focus on subjects who already have symptoms or are at imminent risk of developing disorders related to fundamental aging processes, to use short-term, clinically relevant outcomes, as opposed to long-term outcomes, such as health span or life span, and to validate endpoint measures so they are acceptable to regulatory agencies. Funding is a roadblock, as is shortage of investigators with combined expertise in the basic biology of aging, clinical geriatrics, and investigational new drug clinical trials. Strategies for developing a path from the bench to the bedside are reviewed for interventions that target fundamental aging mechanisms.

AB - Life and health span have been extended in experimental animals using drugs that are potentially translatable into humans. Considerable effort is needed beyond the usual steps in drug development to devise the models, and realistic preclinical and clinical trial strategies are required to advance these agents into clinical application. It will be important to focus on subjects who already have symptoms or are at imminent risk of developing disorders related to fundamental aging processes, to use short-term, clinically relevant outcomes, as opposed to long-term outcomes, such as health span or life span, and to validate endpoint measures so they are acceptable to regulatory agencies. Funding is a roadblock, as is shortage of investigators with combined expertise in the basic biology of aging, clinical geriatrics, and investigational new drug clinical trials. Strategies for developing a path from the bench to the bedside are reviewed for interventions that target fundamental aging mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=84959528564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959528564&partnerID=8YFLogxK

U2 - 10.1101/cshperspect.a025908

DO - 10.1101/cshperspect.a025908

M3 - Article

VL - 6

JO - Cold Spring Harbor perspectives in medicine

JF - Cold Spring Harbor perspectives in medicine

SN - 2157-1422

IS - 3

M1 - a025908

ER -